Welcome to our dedicated page for Trevi Therapeutics SEC filings (Ticker: TRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Trevi Therapeutics, Inc. (TRVI) SEC filings page on Stock Titan provides access to the company’s public reports filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biopharmaceutical company, Trevi uses SEC filings to disclose financial results, material corporate events, and risk factors related to the development of its investigational therapy Haduvio™ (oral nalbuphine extended-release) for chronic cough in idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC).
On this page, you can review current reports on Form 8-K that Trevi files to announce quarterly financial results, changes in key executives, and other significant developments. These 8-K filings often reference press releases that summarize clinical progress, such as data from the Phase 2b CORAL trial in IPF chronic cough and the Phase 2a RIVER trial in RCC, as well as updates on regulatory interactions and planned studies.
In addition to 8-Ks, Trevi’s broader SEC reporting (such as Forms 10-Q and 10-K, when available) contains detailed information on research and development expenses, liquidity, and the risks and uncertainties associated with advancing Haduvio through clinical trials and regulatory review. These documents also describe forward-looking statements regarding future plans for chronic cough indications and capital resources.
Stock Titan’s filings interface is designed to surface Trevi’s SEC documents as they are posted to the EDGAR system and to pair them with AI-generated highlights. These summaries can help explain the key points of lengthy filings, including how Trevi characterizes its clinical-stage status, its focus on IPF, non-IPF ILD, and RCC, and the factors that may affect its business and TRVI stock.
Trevi Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 3, 2026. Holders of common stock as of April 6, 2026, when 128,586,792 shares were outstanding, may vote online.
Proposals include electing one Class I director, ratifying Ernst & Young LLP as auditor for 2026, an advisory “say‑on‑pay” vote, and approving an amended and restated 2019 Stock Incentive Plan that adds 8,000,000 shares to the equity pool. Stockholders are also asked to approve doubling authorized common stock from 200,000,000 to 400,000,000 shares. The board unanimously recommends voting in favor of all proposals.
Trevi Therapeutics is offering 11,600,000 shares of common stock at a public offering price of $13.00 per share, for aggregate gross proceeds of $150,800,000. The underwriters have a 30-day option to purchase up to an additional 1,740,000 shares. Net proceeds are estimated at approximately $141.1 million (no exercise) and $162.4 million (full exercise), after deducting underwriting discounts and commissions. The offering is expected to settle on or about April 20, 2026. Shares outstanding were 128,306,056 as of December 31, 2025. Trevi estimates approximately $171.8 million in cash, cash equivalents and marketable securities as of March 31, 2026 (preliminary). Proceeds are intended to fund Haduvio clinical development (Phase 3 IPF program, Phase 2b non-IPF ILD and RCC trials), working capital and general corporate purposes; Trevi states these resources are expected to be sufficient to fund operations through 2029, based on current plans.
Trevi Therapeutics entered an underwriting agreement for an underwritten public offering of 11,600,000 shares of common stock at $13.00 per share, all sold by the company. Underwriters will buy the shares at $12.22 per share, and have a 30-day option to purchase up to 1,740,000 additional shares at the same terms.
Trevi estimates net proceeds of about $141.1 million, or $162.4 million if the option is fully exercised, to be raised under its effective Form S-3 shelf. It estimates cash, cash equivalents and marketable securities of approximately $171.8 million as of March 31, 2026, and believes existing cash plus offering proceeds will fund operations and planned Haduvio clinical trials through 2029, though not commercialization or all indications, so additional capital will still be required.
Trevi Therapeutics is offering $150,000,000 of common stock, subject to completion. The preliminary prospectus supplement states the underwriters have a 30-day option to purchase up to an additional $22,500,000 of shares. Trevi estimates approximately $171.8 million in cash, cash equivalents and marketable securities as of March 31, 2026. The company plans to use proceeds to fund Haduvio clinical development, including two pivotal Phase 3 trials and other trials described in the prospectus supplement.
Trevi Therapeutics is offering $150,000,000 of common stock, subject to completion. The preliminary prospectus supplement states the underwriters have a 30-day option to purchase up to an additional $22,500,000 of shares. Trevi estimates approximately $171.8 million in cash, cash equivalents and marketable securities as of March 31, 2026. The company plans to use proceeds to fund Haduvio clinical development, including two pivotal Phase 3 trials and other trials described in the prospectus supplement.
Trevi Therapeutics, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to be held June 3, 2026.
Stockholders will vote on six items, including the election of one Class I director, ratification of Ernst & Young LLP as auditor, an advisory approval of executive compensation, approval of an Amended and Restated 2019 Stock Incentive Plan adding 8,000,000 shares, and an amendment to increase authorized common shares from 200,000,000 to 400,000,000.
Only holders of common stock as of the record date, April 6, 2026, may vote; the proxy materials note 128,586,792 shares issued and outstanding as of that record date and report 128,411,048 shares outstanding as of March 31, 2026.
Trevi Therapeutics Inc: An amended Schedule 13G/A filed by The Vanguard Group reports zero shares beneficially owned and 0% of the class as of the filing. The filing explains an internal realignment at The Vanguard Group, Inc. on January 12, 2026 that led certain subsidiaries to report separately.
The filing is administrative: it lists Vanguard's address and states Vanguard and related investment vehicles have the right to receive dividends or proceeds where applicable, and certifies that no single other person holds more than 5% of the class. The form is signed on 03/27/2026.
Trevi Therapeutics is a clinical-stage biopharma company focused on developing Haduvio, an oral extended-release formulation of nalbuphine, to treat chronic cough in idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease and refractory chronic cough (RCC). The drug acts as a kappa agonist and mu antagonist, targeting opioid receptors involved in cough control while aiming to limit abuse risk.
Trevi reported positive Phase 2b CORAL data in IPF-related chronic cough, with Haduvio showing placebo-adjusted reductions in 24-hour cough frequency of roughly 48–60% across dose groups at Week 6, alongside supportive patient-reported outcomes and a safety profile consistent with prior studies. A prior Phase 2a CANAL trial also showed large, statistically significant cough reductions.
In RCC, the Phase 2a RIVER trial demonstrated a 57% placebo‑adjusted reduction in 24‑hour cough frequency and strong responder rates, with no treatment-emergent serious adverse events. Trevi plans two parallel Phase 3 IPF-related chronic cough trials starting in 2026, plus Phase 2b trials in non-IPF ILD cough and RCC, and is running Phase 1 studies on abuse potential, drug-drug interactions and respiratory safety to support a potential NDA.
Trevi Therapeutics reported fourth-quarter and full-year 2025 results and outlined plans to advance its chronic cough pipeline. The company is developing Haduvio, an oral nalbuphine extended-release therapy for chronic cough in idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough.
Trevi ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, which it expects will fund operations into 2028. For 2025, research and development expenses fell to $33.5 million from $39.4 million, while general and administrative costs rose to $15.9 million from $12.1 million. The net loss narrowed to $42.8 million from $47.9 million in 2024.
The company gained overall FDA alignment on its Phase 3 program for IPF-related chronic cough and plans two pivotal Phase 3 trials beginning in 2026. It also plans Phase 2b trials in 2026 for refractory chronic cough and for non-IPF ILD-related chronic cough, and will host an Investor and Analyst Day on May 7, 2026.
Trevi Therapeutics, Inc. is moving its lead program for IPF-related chronic cough into late-stage testing after reaching overall alignment with the U.S. Food and Drug Administration at an End-of-Phase 2 meeting. The company plans two pivotal Phase 3 trials of nalbuphine ER tablets, both randomized, double-blind, placebo-controlled, multicenter and global, using a 54 mg twice-daily dose.
The first trial is planned to enroll about 300 patients with 52 weeks of fixed dosing and a primary endpoint at 24 weeks. The second trial is planned to enroll about 130 patients with 12 weeks of fixed dosing. In both, patients will be randomized 2:1 to nalbuphine ER or placebo, and the primary efficacy endpoint will be the relative change from baseline in 24-hour cough frequency, measured by an objective cough monitor. These designs remain subject to the FDA’s final protocol review.